A critical role of MYC for transformation of human cells by HPV16 E6E7 and oncogenic HRAS

Mako Narisawa-Saito, Yuki Inagawa, Yuki Yoshimatsu, Kei Haga, Katsuyuki Tanaka, Nagayasu Egawa, Shin Ichi Ohno, Hitoshi Ichikawa, Takashi Yugawa, Masatoshi Fujita, Tohru Kiyono

研究成果: ジャーナルへの寄稿記事

9 引用 (Scopus)

抄録

Human papillomaviruses (HPVs) are the primary causal agents for development of cervical cancer, and deregulated expression of two viral oncogenes E6 and E7 is considered to contribute to disease initiation. Recently, we have demonstrated that transduction of oncogenic HRAS (HRAS. G12V) and MYC together with HPV16 E6E7 is sufficient for tumorigenic transformation of normal human cervical keratinocytes (HCKs). Here, we show that transduction of HRAS. G12V on the background of E6E7 expression causes accumulation of MYC protein and tumorigenic transformation of not only normal HCKs but also other normal primary human cells, including tongue keratinocytes and bronchial epithelial cells as well as hTERT-immortalized foreskin fibroblasts. Subcutaneous transplantation of as few as 200 HCKs expressing E6E7 and HRAS. G12V resulted in tumor formation within 2 months. Dissecting RAS signaling pathways, constitutively active forms of AKT1 or MEK1 did not result in tumor formation with E6E7, but tumorigenic transformation was induced with addition of MYC. Increased MYC expression endowed resistance to calcium- and serum-induced terminal differentiation and activated the mammalian target of rapamycin (mTOR) pathway. An mTOR inhibitor (Rapamycin) and MYC inhibition a level not affecting proliferation in culture both markedly suppressed tumor formation by HCKs expressing E6E7 and HRAS. G12V. These results suggest that a single mutation of HRAS could be oncogenic in the background of deregulated expression of E6E7 and MYC plays a critical role in cooperation with the RAS signaling pathways in tumorigenesis. Thus inhibition of MYC and/or the downstream mTOR pathway could be a therapeutic strategy not only for the MYC-altered but also RAS-activated cancers.

元の言語英語
ページ(範囲)910-917
ページ数8
ジャーナルCarcinogenesis
33
発行部数4
DOI
出版物ステータス出版済み - 4 16 2012

Fingerprint

Keratinocytes
Neoplastic Cell Transformation
Sirolimus
Neoplasms
Foreskin
Oncogenes
Tongue
Uterine Cervical Neoplasms
Carcinogenesis
Fibroblasts
Transplantation
Epithelial Cells
Calcium
Mutation
Serum
Proteins
Therapeutics

All Science Journal Classification (ASJC) codes

  • Cancer Research

これを引用

Narisawa-Saito, M., Inagawa, Y., Yoshimatsu, Y., Haga, K., Tanaka, K., Egawa, N., ... Kiyono, T. (2012). A critical role of MYC for transformation of human cells by HPV16 E6E7 and oncogenic HRAS. Carcinogenesis, 33(4), 910-917. https://doi.org/10.1093/carcin/bgs104

A critical role of MYC for transformation of human cells by HPV16 E6E7 and oncogenic HRAS. / Narisawa-Saito, Mako; Inagawa, Yuki; Yoshimatsu, Yuki; Haga, Kei; Tanaka, Katsuyuki; Egawa, Nagayasu; Ohno, Shin Ichi; Ichikawa, Hitoshi; Yugawa, Takashi; Fujita, Masatoshi; Kiyono, Tohru.

:: Carcinogenesis, 巻 33, 番号 4, 16.04.2012, p. 910-917.

研究成果: ジャーナルへの寄稿記事

Narisawa-Saito, M, Inagawa, Y, Yoshimatsu, Y, Haga, K, Tanaka, K, Egawa, N, Ohno, SI, Ichikawa, H, Yugawa, T, Fujita, M & Kiyono, T 2012, 'A critical role of MYC for transformation of human cells by HPV16 E6E7 and oncogenic HRAS', Carcinogenesis, 巻. 33, 番号 4, pp. 910-917. https://doi.org/10.1093/carcin/bgs104
Narisawa-Saito M, Inagawa Y, Yoshimatsu Y, Haga K, Tanaka K, Egawa N その他. A critical role of MYC for transformation of human cells by HPV16 E6E7 and oncogenic HRAS. Carcinogenesis. 2012 4 16;33(4):910-917. https://doi.org/10.1093/carcin/bgs104
Narisawa-Saito, Mako ; Inagawa, Yuki ; Yoshimatsu, Yuki ; Haga, Kei ; Tanaka, Katsuyuki ; Egawa, Nagayasu ; Ohno, Shin Ichi ; Ichikawa, Hitoshi ; Yugawa, Takashi ; Fujita, Masatoshi ; Kiyono, Tohru. / A critical role of MYC for transformation of human cells by HPV16 E6E7 and oncogenic HRAS. :: Carcinogenesis. 2012 ; 巻 33, 番号 4. pp. 910-917.
@article{5292c078fc1f40a1b9327886521e77c7,
title = "A critical role of MYC for transformation of human cells by HPV16 E6E7 and oncogenic HRAS",
abstract = "Human papillomaviruses (HPVs) are the primary causal agents for development of cervical cancer, and deregulated expression of two viral oncogenes E6 and E7 is considered to contribute to disease initiation. Recently, we have demonstrated that transduction of oncogenic HRAS (HRAS. G12V) and MYC together with HPV16 E6E7 is sufficient for tumorigenic transformation of normal human cervical keratinocytes (HCKs). Here, we show that transduction of HRAS. G12V on the background of E6E7 expression causes accumulation of MYC protein and tumorigenic transformation of not only normal HCKs but also other normal primary human cells, including tongue keratinocytes and bronchial epithelial cells as well as hTERT-immortalized foreskin fibroblasts. Subcutaneous transplantation of as few as 200 HCKs expressing E6E7 and HRAS. G12V resulted in tumor formation within 2 months. Dissecting RAS signaling pathways, constitutively active forms of AKT1 or MEK1 did not result in tumor formation with E6E7, but tumorigenic transformation was induced with addition of MYC. Increased MYC expression endowed resistance to calcium- and serum-induced terminal differentiation and activated the mammalian target of rapamycin (mTOR) pathway. An mTOR inhibitor (Rapamycin) and MYC inhibition a level not affecting proliferation in culture both markedly suppressed tumor formation by HCKs expressing E6E7 and HRAS. G12V. These results suggest that a single mutation of HRAS could be oncogenic in the background of deregulated expression of E6E7 and MYC plays a critical role in cooperation with the RAS signaling pathways in tumorigenesis. Thus inhibition of MYC and/or the downstream mTOR pathway could be a therapeutic strategy not only for the MYC-altered but also RAS-activated cancers.",
author = "Mako Narisawa-Saito and Yuki Inagawa and Yuki Yoshimatsu and Kei Haga and Katsuyuki Tanaka and Nagayasu Egawa and Ohno, {Shin Ichi} and Hitoshi Ichikawa and Takashi Yugawa and Masatoshi Fujita and Tohru Kiyono",
year = "2012",
month = "4",
day = "16",
doi = "10.1093/carcin/bgs104",
language = "English",
volume = "33",
pages = "910--917",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - A critical role of MYC for transformation of human cells by HPV16 E6E7 and oncogenic HRAS

AU - Narisawa-Saito, Mako

AU - Inagawa, Yuki

AU - Yoshimatsu, Yuki

AU - Haga, Kei

AU - Tanaka, Katsuyuki

AU - Egawa, Nagayasu

AU - Ohno, Shin Ichi

AU - Ichikawa, Hitoshi

AU - Yugawa, Takashi

AU - Fujita, Masatoshi

AU - Kiyono, Tohru

PY - 2012/4/16

Y1 - 2012/4/16

N2 - Human papillomaviruses (HPVs) are the primary causal agents for development of cervical cancer, and deregulated expression of two viral oncogenes E6 and E7 is considered to contribute to disease initiation. Recently, we have demonstrated that transduction of oncogenic HRAS (HRAS. G12V) and MYC together with HPV16 E6E7 is sufficient for tumorigenic transformation of normal human cervical keratinocytes (HCKs). Here, we show that transduction of HRAS. G12V on the background of E6E7 expression causes accumulation of MYC protein and tumorigenic transformation of not only normal HCKs but also other normal primary human cells, including tongue keratinocytes and bronchial epithelial cells as well as hTERT-immortalized foreskin fibroblasts. Subcutaneous transplantation of as few as 200 HCKs expressing E6E7 and HRAS. G12V resulted in tumor formation within 2 months. Dissecting RAS signaling pathways, constitutively active forms of AKT1 or MEK1 did not result in tumor formation with E6E7, but tumorigenic transformation was induced with addition of MYC. Increased MYC expression endowed resistance to calcium- and serum-induced terminal differentiation and activated the mammalian target of rapamycin (mTOR) pathway. An mTOR inhibitor (Rapamycin) and MYC inhibition a level not affecting proliferation in culture both markedly suppressed tumor formation by HCKs expressing E6E7 and HRAS. G12V. These results suggest that a single mutation of HRAS could be oncogenic in the background of deregulated expression of E6E7 and MYC plays a critical role in cooperation with the RAS signaling pathways in tumorigenesis. Thus inhibition of MYC and/or the downstream mTOR pathway could be a therapeutic strategy not only for the MYC-altered but also RAS-activated cancers.

AB - Human papillomaviruses (HPVs) are the primary causal agents for development of cervical cancer, and deregulated expression of two viral oncogenes E6 and E7 is considered to contribute to disease initiation. Recently, we have demonstrated that transduction of oncogenic HRAS (HRAS. G12V) and MYC together with HPV16 E6E7 is sufficient for tumorigenic transformation of normal human cervical keratinocytes (HCKs). Here, we show that transduction of HRAS. G12V on the background of E6E7 expression causes accumulation of MYC protein and tumorigenic transformation of not only normal HCKs but also other normal primary human cells, including tongue keratinocytes and bronchial epithelial cells as well as hTERT-immortalized foreskin fibroblasts. Subcutaneous transplantation of as few as 200 HCKs expressing E6E7 and HRAS. G12V resulted in tumor formation within 2 months. Dissecting RAS signaling pathways, constitutively active forms of AKT1 or MEK1 did not result in tumor formation with E6E7, but tumorigenic transformation was induced with addition of MYC. Increased MYC expression endowed resistance to calcium- and serum-induced terminal differentiation and activated the mammalian target of rapamycin (mTOR) pathway. An mTOR inhibitor (Rapamycin) and MYC inhibition a level not affecting proliferation in culture both markedly suppressed tumor formation by HCKs expressing E6E7 and HRAS. G12V. These results suggest that a single mutation of HRAS could be oncogenic in the background of deregulated expression of E6E7 and MYC plays a critical role in cooperation with the RAS signaling pathways in tumorigenesis. Thus inhibition of MYC and/or the downstream mTOR pathway could be a therapeutic strategy not only for the MYC-altered but also RAS-activated cancers.

UR - http://www.scopus.com/inward/record.url?scp=84859570193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859570193&partnerID=8YFLogxK

U2 - 10.1093/carcin/bgs104

DO - 10.1093/carcin/bgs104

M3 - Article

C2 - 22345164

AN - SCOPUS:84859570193

VL - 33

SP - 910

EP - 917

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 4

ER -